Head-to-head evidence
Alectinib vs Ensartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Alectinib · Alecensa
Marketed by Roche
NCT02075840 · Phase 3 · completed
Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.
Next expected readout: November 2026 · NCT05987956 (registry estimate)
Ensartinib
Marketed by Xcovery Holdings
NCT01625234 · Phase 1/2 · completed
This was a non-randomized, open-label, single-arm study with 131 participants and no placebo or active comparator. Its primary endpoint was the maximum tolerated dose, a dose-finding safety outcome rather than a clinical efficacy endpoint, so the findings provide limited controlled evidence for ensartinib’s treatment benefit.
Next expected readout: February 2027 · NCT05241028 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · Ensartinib's landscape